Drug Profile
Research programme: oral peptides - Aquestive Therapeutics
Alternative Names: Exenatide buccal delivery - Aquestive TherapeuticsLatest Information Update: 10 Apr 2018
Price :
$50
*
At a glance
- Originator MonoSol Rx
- Developer Aquestive Therapeutics
- Class Peptides
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Unspecified